β€’ Bones & Joints β€’ Brain & Nerves πŸŽ—οΈ Cancer β€’ Diabetes & Weight β€’ Gut & Digestion β€’ Heart & Circulation β€’ Infections & Vaccines β€’ Lung & Breathing β€’ Mens Health 🧠 Mental Health 🧴 Skin β€’ Womens Health

NHS-sourced information. This is general health information β€” not personal medical advice. Always speak to your GP or specialist about your health.

HomeCancerA Study to Evaluate the Safety and Efficacy…

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

25 March 2026 Read original ↗
🅇 This trial is currently recruiting participants in the UK
Speak to your GP or specialist first. They can help you understand if you might be eligible and what taking part would involve.

πŸ”¬ This trial is currently recruiting participants

If you match the criteria below, you may be able to take part. Ask your doctor about this trial or contact the trial team directly.

Status
Recruiting
Trial Phase
PHASE2
Who Can Join
ALL
Age Range
18 Years – Any

About This Trial

The purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer

Run by

Bristol-Myers Squibb

βš•οΈ Before you apply: Talk to your GP or specialist about whether this trial might be right for you. Never stop existing treatment without medical advice. Trial ID: NCT07221357
Share: Facebook Twitter/X Source: Original ↗

Related: Cancer